- Home
- FLGC vs CMMB Comparison
FLGC vs CMMB Comparison
Compare FLGC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- CMMB
- Stock Information
- Founded
- FLGC 2019
- CMMB 2004
- Country
- FLGC United States
- CMMB Israel
- Employees
- FLGC N/A
- CMMB N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- CMMB Health Care
- Exchange
- FLGC Nasdaq
- CMMB Nasdaq
- Market Cap
- FLGC 13.5M
- CMMB 13.7M
- IPO Year
- FLGC 2021
- CMMB N/A
- Fundamental
- Price
- FLGC $18.60
- CMMB $3.39
- Analyst Decision
- FLGC Strong Buy
- CMMB Strong Buy
- Analyst Count
- FLGC 1
- CMMB 2
- Target Price
- FLGC $156.00
- CMMB $26.50
- AVG Volume (30 Days)
- FLGC 106.0K
- CMMB 273.6K
- Earning Date
- FLGC 11-12-2025
- CMMB 11-13-2025
- Dividend Yield
- FLGC N/A
- CMMB N/A
- EPS Growth
- FLGC N/A
- CMMB N/A
- EPS
- FLGC N/A
- CMMB N/A
- Revenue
- FLGC $52,373,000.00
- CMMB N/A
- Revenue This Year
- FLGC N/A
- CMMB N/A
- Revenue Next Year
- FLGC $10.22
- CMMB N/A
- P/E Ratio
- FLGC N/A
- CMMB N/A
- Revenue Growth
- FLGC N/A
- CMMB N/A
- 52 Week Low
- FLGC $15.15
- CMMB $2.39
- 52 Week High
- FLGC $82.25
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- FLGC 46.61
- CMMB 64.46
- Support Level
- FLGC $17.80
- CMMB $3.11
- Resistance Level
- FLGC $20.45
- CMMB $3.50
- Average True Range (ATR)
- FLGC 1.61
- CMMB 0.22
- MACD
- FLGC -0.26
- CMMB 0.01
- Stochastic Oscillator
- FLGC 41.27
- CMMB 80.00
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.